The RNASEL Arg462Gln polymorphism was implicated in up to 13% of prostate cancer cases, with the resultant enzyme 3 times less active than the wildtype enzyme, and an association was found among Europeans and Africans between the RNASEL Arg462Gln polymorphism and sporadic prostate cancer risk[14]. This evidence concerns the gene RNASEL and prostate cancer.